星空体育官方入口网站网址大全-登录入口官网

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2023-12-01 ms3000000795637810 来自江苏省

审稿速度:24.0 | 投稿命中率:75.0
经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了

41 0

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2023-08-27 ms8000002057789160 来自江苏省

偏重的研究方向：糖尿病
经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志

65 0

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2022-03-05 nimeide123

投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。

92 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2023-02-11 ms8000000834758423 来自广东省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：糖尿病;临床
经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯

64 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2023-01-15 ms8000001945466546 来自江苏省

审稿速度:24.0 | 投稿命中率:5.0
经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！

79 0

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2022-09-28 我很焦急

审稿速度:12.0 | 投稿命中率:50.0
经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。

76 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2021-12-02 Lijx1367

5个月后告诉你找不到审稿人

123 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2022-02-09 wkw0722

可以共通讯吗

102 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2022-04-28 ms5000001070060621

偏重的研究方向：脑;糖尿病;临床
经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中

103 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2172289, encodeId=14bc21e228969, content=审稿速度:24.0 | 投稿命中率:75.0 经验分享：一审将近5个月，意见回来小修，修改提交后4个月了没消息，发邮件问说找不到review。。。再也不投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4975729351, createdName=ms3000000795637810, createdTime=Fri Dec 01 11:05:13 CST 2023, time=2023-12-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2154784, encodeId=ec172154e84fc, content=偏重的研究方向：糖尿病 经验分享：求求大家不要投这个杂志，等了一个月都没有分学术编辑，幸好及时撤稿。最离谱的杂志 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=936d8598441, createdName=ms8000002057789160, createdTime=Sun Aug 27 11:48:46 CST 2023, time=2023-08-27, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1199695, encodeId=f0f711996951b, content=投稿两个月没动静，发邮件撤稿，同意，改投。结果又过了两个月来个审稿意见，小修。直接拒绝修改。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/c06abf4cec63a49eacb0ac6e07f0bcf6.jpg, createdBy=3ffb40995, createdName=nimeide123, createdTime=Sat Mar 05 17:10:53 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114127, encodeId=8798211412e6d, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：糖尿病;临床 经验分享：2022年9月下旬投的一篇meta分析 2022年12月下旬给了大修修完后1月下旬发回 2月上旬直接接收了总体编辑还可以，reviewer意见很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ec488146048, createdName=ms8000000834758423, createdTime=Sat Feb 11 16:24:51 CST 2023, time=2023-02-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110296, encodeId=ac412110296c0, content=审稿速度:24.0 | 投稿命中率:5.0 经验分享：2022.8.24投稿，一直AE invited，半个月前催了一次，然后三天前被撤稿了，说找不到审稿人。。。。太坑了！！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ba15449837, createdName=ms8000001945466546, createdTime=Sun Jan 15 12:37:01 CST 2023, time=2023-01-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2090760, encodeId=60e32090e6092, content=审稿速度:12.0 | 投稿命中率:50.0 经验分享：投稿2个月，还在AE INVITED,真慢，考虑撤稿了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4635207284, createdName=我很焦急, createdTime=Wed Sep 28 08:01:22 CST 2022, time=2022-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076339, encodeId=91a310e6339b4, content=5个月后告诉你找不到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211202/91aa9390b9724e9b8fec658e372334af/ded8019134da4d988b474946a2695c55.jpg, createdBy=71262764624, createdName=Lijx1367, createdTime=Thu Dec 02 21:43:33 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191484, encodeId=8f1611914840f, content=可以共通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Wed Feb 09 18:07:52 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215318, encodeId=0e501215318d1, content=偏重的研究方向：脑;糖尿病;临床 经验分享：****：4.011 Q3 投稿时间2022-04-19 等待分配编辑中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fd45695826, createdName=ms5000001070060621, createdTime=Thu Apr 28 15:01:36 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230627, encodeId=073e123062e92, content=二修后pending approval大概要持续多久呀？有可能被拒吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1aa4732935, createdName=wkw0722, createdTime=Tue Jul 05 09:26:25 CST 2022, time=2022-07-05, status=1, ipAttribution=)]

2022-07-05 wkw0722

二修后pending approval大概要持续多久呀？有可能被拒吗？

96 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务